Exit off canvas

Personal Information



First Name


Last Name



Dr. Eric Horlick is an interventional cardiologist at the Peter Munk Cardiac Centre and an Assistant Professor of Medicine at University of Toronto. Since obtaining his medical degree from McGill University in Montreal, Quebec in 1996, Dr. Horlick has been the recipient of the Sanofi Cardiovascular Research Fellowship and the Julio Chavez Young Investigator Award from the International Congress of Cardiology among other honours. He has also co-authored many studies in respected publications, including American Heart Journal, Circulation, Journal of the American College of Cardiology, Heart and the International Journal of Cardiology, and has been invited to speak to physician audiences in the United States, Canada, Australia, Germany and Saudi Arabia. He is a member of the American College of Cardiology and a Fellow of the Society for Cardiovascular angiography and intervention.

Dr. Horlick started his career at University Health Network as a fellow studying percutaneous (through the skin) coronary intervention, and proceeded to do research in and training adult congenital interventional cardiology. Dr. Horlick’s expertise lies in performing surgical or minimally invasive procedures to treat structural heart disease. He is considered a key opinion leader in transcatheter valve therapies for the aortic and pulmonary valves. He works closely with the Division of Cardiovascular Surgery at the University Health Network. In a ground breaking surgical intervention in 2006, Dr. Horlick and a team of surgeons at Toronto General Hospital performed a new edge-to-edge percutaneous mitral valve repair on a patient with a leaking heart valve. The condition usually requires open-heart surgery, but with this new technique, patients recover faster and have reduced hospital stays. Dr. Horlick continues to work with the latest valve replacement technology to improve surgical outcomes and patients’ quality of life. Dr. Horlick recently provided physician training to all of Europe for a new Transcatheter Pulmonary Valve. He is actively involved in training physicians around the world in new structural and valvular heart disease therapies.